Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration

LM Khachigian, G Liew, KYC Teo, TY Wong… - Journal of translational …, 2023‏ - Springer
Neovascular age-related macular degeneration (nAMD) is a major cause of visual
impairment and blindness. Anti-vascular endothelial growth factor (VEGF) agents, such as …

Anti-VEGF-resistant retinal diseases: a review of the latest treatment options

JO Wallsh, RP Gallemore - Cells, 2021‏ - mdpi.com
Anti-vascular endothelial growth factor (anti-VEGF) therapy currently plays a central role in
the treatment of numerous retinal diseases, most notably exudative age-related macular …

Mechanisms of macular edema

CD Haydinger, LB Ferreira, KA Williams… - Frontiers in …, 2023‏ - frontiersin.org
Macular edema is the pathological accumulation of fluid in the central retina. It is a
complication of many retinal diseases, including diabetic retinopathy, retinal vascular …

[HTML][HTML] Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence

RM Hanna, M Barsoum, F Arman, U Selamet… - Kidney international, 2019‏ - Elsevier
Vascular endothelial growth factor (VEGF) inhibitors have emerged as powerful tools to treat
malignant neoplasms and ocular diseases by virtue of their ability to inhibit angiogenesis …

Intravitreal anti-VEGF agents and cardiovascular risk

M Porta, E Striglia - Internal and emergency medicine, 2020‏ - Springer
Abstract Antagonists of Vascular Endothelial Growth Factor (Anti-VEGF) are widely
administered by intravitreal injection for the treatment of ocular pathologies such as Age …

Phase 1 study of OPT-302 inhibition of vascular endothelial growth factors C and D for neovascular age-related macular degeneration

PU Dugel, DS Boyer, AN Antoszyk, NC Steinle… - Ophthalmology …, 2020‏ - Elsevier
Purpose OPT-302 is a novel inhibitor of vascular endothelial growth factor (VEGF)-C and
VEGF-D. A phase 1 trial assessed the safety of intravitreal OPT-302 as monotherapy or …

Discovery of aptamers and the acceleration of the development of targeting research in ophthalmology

J Cao, F Zhang, W **ong - International Journal of Nanomedicine, 2023‏ - Taylor & Francis
Aptamers are widely applied to diagnosis and therapy because of their targeting. However,
the current progress of research into aptamers for the treatment of eye disorders has not …

From randomised controlled trials to real-world data: Clinical evidence to guide management of diabetic macular oedema

PH Gabrielle, H Mehta, D Barthelmes, V Daien… - Progress in Retinal and …, 2023‏ - Elsevier
Randomised clinical trials (RCTs) are generally considered the gold-standard for providing
scientific evidence for treatments' effectiveness and safety but their findings may not always …

[HTML][HTML] Frequency of intravitreal anti-VEGF injections and risk of death: a systematic review with meta-analysis

M Reibaldi, M Fallico, T Avitabile, P Marolo, G Parisi… - Ophthalmology …, 2022‏ - Elsevier
Topic To investigate whether an increasing number of intravitreal anti-VEGF injections is
associated with a higher mortality risk. Clinical Relevance The issue of systemic safety of …